IDIX (MM)

"Vertex: FDA Puts Partial Hold on Study of Hepatitis C Drug," at 6:07 p.m. ET, mistakenly implied in the fourth paragraph that no serious adverse events or safety issues were reported in studies of the drug at any dose. It should have specified that in patients who were given 100-milligram or 200-milligram doses of the drug in the European study, no serious adverse events or liver or cardiac safety issues were reported.

Subscribe to WSJ: http://online.wsj.com?mod=djnwires